New pill takes on Virus-Linked lymphoma in early trial
Disease control
Not yet recruiting
This early-phase trial tests an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants will take one of three daily doses (600, 1200, or 1800 mg) in 28-day…
Phase: PHASE1 • Sponsor: Pierluigi Porcu • Aim: Disease control
Last updated Jun 24, 2026 07:04 UTC